Distinct Cancer-Specific Survival in Metastatic Prostate Cancer Patients Classified by a Panel of Single Nucleotide Polymorphisms of Cancer-Associated Genes

Genes and Cancer

Volumn 4, Issue 1-2, 2013, Pages 54-60

  Tsuchiya, Norihiko ^a   Matsui, Shigeyuki ^b   Narita, Shintaro ^a   Kamba, Tomomi ^c   Mitsuzuka, Koji ^d   Hatakeyama, Shingo ^e   Horikawa, Yohei ^a   Inoue, Takamitsu ^a   Saito, Seiichi ^f   Ohyama, Chikara ^e   Arai, Yoich ^d   Ogawa, Osamu ^c   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

bone metastasis; prostate cancer; single nucleotide polymorphism; survival

Indexed keywords

CASPASE 8; CELL PROTEIN; DNA; DOCETAXEL; GONADORELIN; INTERLEUKIN 13; POSTMEIOTIC SEGREGATION INCREASED 1 PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; XRCC4 PROTEIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CASP8 GENE; GATA3 GENE; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; IGF1 GENE; IL13 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PMS1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; XRCC4 GENE;

EID: 84887458592     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913481354     Document Type: Article

References (23)

1. Gudmundsson J,Sulem P,Gudbjartsson DF, et al.Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.Nat Genet. 2009;41:1122-6.
2. Eeles RA,Kote-Jarai Z,Al Olama AA, et al.Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.Nat Genet. 2009;41:1116-21.
3. Takata R,Akamatsu S,Kubo M, et al.Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population.Nat Genet. 2010;42:751-4.
4. Yeager M,Chatterjee N,Ciampa J, et al.Identification of a new prostate cancer susceptibility locus on chromosome 8q24.Nat Genet. 2009;41:1055-7.
5. Eeles RA,Kote-Jarai Z,Giles GG, et al.Multiple newly identified loci associated with prostate cancer susceptibility.Nat Genet. 2008;40:316-21.
6. Habuchi T.Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model.Future Oncol. 2006;2:233-45.
7. Tsuchiya N,Wang L,Horikawa Y, et al.CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.Int J Oncol. 2005;26:225-31.
8. Suzuki K,Nakazato H,Matsui H, et al.Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population.Anticancer Res. 2003;23:4941-6.
9. Tsuchiya N,Wang L,Suzuki H, et al.Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.J Clin Oncol. 2006;24:1982-9.
10. Frullanti E,Galvan A,Falvella FS, et al.Multiple genetic loci modulate lung adenocarcinoma clinical staging.Clin Cancer Res. 2011;17:2410-6.
11. Huang YT,Heist RS,Chirieac LR, et al.Genome-wide analysis of survival in early-stage non-small-cell lung cancer.J Clin Oncol. 2009;27:2660-7.
12. Andrew AS,Gui J,Sanderson AC, et al.Bladder cancer SNP panel predicts susceptibility and survival.Hum Genet. 2009;125:527-39.
13. Penney KL,Pyne S,Schumacher FR, et al.Genome-wide association study of prostate cancer mortality.Cancer Epidemiol Biomarkers Prev. 2010;19:2869-76.
14. Lin DW,FitzGerald LM,Fu R, et al.Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.Cancer Epidemiol Biomarkers Prev. 2011;20:1928-36.
15. Roemeling S,Roobol MJ,Gosselaar C,Schroder FH.Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Prostate. 2006;66:1076-81.
16. Tannock IF,de Wit R,Berry WR, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004;351:1502-12.
17. Walko CM,McLeod H.Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.Nat Clin Pract Oncol. 2009;6:153-62.
18. Sharifi N,Dahut WL,Figg WD.The genetics of castration-resistant prostate cancer: what can the germline tell us?.Clin Cancer Res. 2008;14:4691-3.
19. Joyce JA.Therapeutic targeting of the tumor microenvironment.Cancer Cell. 2005;7:513-20.
20. Mohler JL,Gregory CW,Ford OH, et al.The androgen axis in recurrent prostate cancer.Clin Cancer Res. 2004;10:440-8.
21. Packer BR,Yeager M,Staats B, et al.SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes.Nucleic Acids Res. 2004;32:D528-32.
22. Matsui S.Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays.BMC Bioinformatics. 2006;7:156.
23. Radmacher MD,McShane LM,Simon R.A paradigm for class prediction using gene expression profiles.J Comput Biol. 2002;9:505-11.